Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

Leukemia

Volumn 29, Issue 4, 2015, Pages 783-787

  Kamel, S ^a   Horton, L ^a   Ysebaert, L ^b   Levade, M ^c,d   Burbury, K ^e   Tan, S ^a   Cole Sinclair, M ^a   Reynolds, J ^f   Filshie, R ^a   Schischka, S ^a   Khot, A ^e   Sandhu, S ^e   Keating, M J ^g   Nandurkar, H ^a,h   Tam, C S ^a,e,h  

^a ST VINCENT S HOSPITAL   (Australia)

^b Serv d'Hematologie de l'Enfant   (France)

^c INSERM   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f DEAKIN UNIVERSITY   (Australia)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BRUTON TYROSINE KINASE; CLOPIDOGREL; COLLAGEN; IBRUTINIB; RIVAROXABAN; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COLLAGEN DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; EX VIVO STUDY; FEMALE; HEMATOMA; HUMAN; IN VIVO STUDY; LIGHT TRANSMISSION AGGREGOMETRY; MALE; MANTLE CELL LYMPHOMA; MEDIATOR; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CELLS, CULTURED; COLLAGEN; FEMALE; HEMORRHAGE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PLATELET AGGREGATION; PYRAZOLES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX;

EID: 84927583205     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.247     Document Type: Article

References (15)

1. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
2. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
3. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
4. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
5. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8: 1137-1140.
6. Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood 2003; 102: 3592-3599.
7. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-13080.
8. Farooqui M, Lozier JN, Valdez J, Saba N, Wells A, Soto S et al. Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. ASH Annual Meeting Abstracts 2012; 120: 1789.
9. Rushworth SA, MacEwan DJ, Bowles KM. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369: 1277-1278.
10. Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2011; (1): CD005158.
11. Lewis BB, Bates I. Dacie and Lewis Practical Haematology. 10th edn. Churchill Livingstone, Elsevier, 2006.
12. Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P et al. The new tyrosinekinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114: 1884-1892.
13. Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW et al. X-linked agammaglobulinemia: Report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85: 193-202.
14. Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139: 363-372.
15. Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 2012; 10: 2418-2427.